Kazia Therapeutics
KZIA
7 hedge funds and large institutions have $353K invested in Kazia Therapeutics in 2016 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
13% less funds holding
Funds holding: 8 → 7 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
48% less capital invested
Capital invested by funds: $680K → $353K (-$327K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$58.6K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$1.34K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$335 |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$335 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$149K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$46K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$35K |
| 4 |
CWM
Cornerstone Wealth Management
St. Peters,
Missouri
|
-$25K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$335 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Renaissance Technologies
New York
| $201K | – | – | – |
|
|
2
Morgan Stanley
New York
| $145K | +$58.6K | +175 | +55% |
|
|
3
UBS Group
Zurich,
Switzerland
| $7K | +$1.34K | +4 | +21% |
|
|
4
Bank of America
Charlotte,
North Carolina
| – | -$149K | -444 | -100% |
|
|
VKH
5
Virtu KCG Holdings
New York
| – | -$46K | -119 | Closed |
|
|
6
Citadel Advisors
Miami,
Florida
| – | -$35K | -88 | Closed |
|
|
CWM
7
Cornerstone Wealth Management
St. Peters,
Missouri
| – | -$25K | -66 | Closed |
|
|
8
Creative Planning
Overland Park,
Kansas
| – | -$335 | -1 | -50% |
|
|
9
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$335 | +1 | New |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| – | +$335 | +1 | New |
|
KZIA Hedge Fund Activity: Q4 2016 in Review
7 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q4 2016, worth a combined $353K — down 48% from $680K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of KZIA and 2 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.
The largest buyer was Morgan Stanley, adding an estimated $58.6K. The largest seller was Bank of America, cutting an estimated $149K.
- 7 institutional investors held Kazia Therapeutics (KZIA) as of Q4 2016, down from 8 in Q3 2016.
- Funds reported $353K of Kazia Therapeutics stock for Q4 2016, down 48% quarter-over-quarter.
- 2 funds opened new Kazia Therapeutics positions in Q4 2016 and 3 closed out, a net change of -1 holder.
- The largest Kazia Therapeutics buyer in Q4 2016 was Morgan Stanley, an estimated $58.6K added.
- The largest Kazia Therapeutics seller in Q4 2016 was Bank of America, an estimated $149K sold.
Based on aggregated 13F filings for Q4 2016.